Welcome to our dedicated page for Fennec Pharmaceuticals news (Ticker: FENC), a resource for investors and traders seeking the latest updates and insights on Fennec Pharmaceuticals stock.
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX) is a specialty pharmaceutical company focused on reducing cisplatin-induced ototoxicity in cancer patients through its therapy PEDMARK®. The FENC news feed on Stock Titan aggregates company announcements, clinical updates, capital markets activity and regulatory developments that shape the outlook for this ototoxicity-focused business.
Investors and healthcare observers can review news about regulatory and commercial milestones for PEDMARK® in the United States and PEDMARQSI® in Europe and the U.K., as well as licensing developments with Norgine Pharmaceuticals Ltd. Updates on investigator-initiated and investigator-sponsored trials, including studies in Japan and at institutions such as City of Hope, provide insight into how PEDMARK® is being evaluated across different tumor types, age groups and geographies.
The Fennec news stream also covers financing transactions and balance sheet actions, such as underwritten public offerings of common shares, non-brokered offerings in Canada, and the use of proceeds to repurchase and redeem senior secured floating rate convertible notes issued to Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP. These items help investors understand how the company funds commercialization and clinical collaborations while managing its capital structure.
Additional releases may highlight participation in healthcare conferences, changes in institutional shareholdings, and other corporate communications. By following this page, readers can access an organized view of Fennec’s official disclosures, from clinical data readouts and commercialization updates to securities offerings and debt redemptions, all in one place.
Fennec Pharmaceuticals (NASDAQ: FENC) reported Q3 2025 results on November 13, 2025: net product sales $12.5M (≈79% YoY) and the company said it achieved its first positive cash flow from operations, with cash and cash equivalents rising to $21.9M as of September 30, 2025. The company recorded a small loss of $0.6M for the quarter and operating loss of $0.19M. Management highlighted accelerating adoption of PEDMARK across major oncology networks and investigator-led studies in review. Preliminary results from the Japan STS-J01 trial are expected in Q4 2025, with potential pursuit of registration and partnering if data are positive.
Fennec Pharmaceuticals (NASDAQ:FENC) reported strong Q2 2025 financial results, with total net revenues of $9.7 million, representing a 33% increase from Q2 2024. The company's flagship product PEDMARK® showed significant growth in both large community practices and academic centers.
Key highlights include the addition of PEDMARK® to a large national oncology group's formulary for patients under 40, continued expansion of the Fennec HEARS™ patient support program, and successful initial uptake of PEDMARQSI® in the UK and Germany. The company strengthened its patent portfolio with a new U.S. patent providing protection until 2039.
Financial results show operating expenses of $12.4 million and a net loss of $3.2 million for Q2 2025. Cash position stood at $18.7 million as of June 30, 2025. The company expects Japan Clinical Trial (STS-J01) results in H2 2025.
Fennec Pharmaceuticals (NASDAQ: FENC), a commercial stage specialty pharmaceutical company, has scheduled its second quarter 2025 financial results announcement for Thursday, August 14, 2025. The results will be released before U.S. markets open, followed by a management conference call and webcast at 8:30 a.m. Eastern Time.
The company will host a live webcast accessible through their website, with a replay available for thirty days following the event. Participants are advised to connect at least 15 minutes early to allow for any necessary software downloads.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) has scheduled the release of its first quarter 2025 financial results for Tuesday, May 13, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss their financial and business results.
Interested parties can access the webcast through the company's website at www.fennecpharma.com under the Investors & Media section. Participants are advised to connect at least 15 minutes before the call to allow time for any necessary software downloads. A replay of the webcast will be available on the company's website for 30 days following the event.
Fennec Pharmaceuticals (NASDAQ:FENC) reported strong financial results for Q4 and full-year 2024, with PEDMARK® net product sales reaching $29.6 million for the year, a 40% increase from 2023. Q4 2024 sales were $7.9 million, up 13% from Q3.
The company ended 2024 with $26.6 million in cash and equivalents, strengthened by a $43 million upfront payment from the Norgine transaction. Fennec completed early repayment of $13 million of convertible debt, saving approximately $1.5 million in annual interest payments.
Key developments include PEDMARQSI® commercial launches in the UK and Germany, positive NICE recommendation, and continued momentum in the Adolescent and Young Adult segment. The Japan clinical trial (STS-J01) results are expected in H2 2025. Operating expenses increased year-over-year, with selling and marketing at $18.4 million and G&A at $23.1 million for FY 2024.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) has scheduled the release of its full year and fourth quarter 2024 financial results for Monday, March 10, 2025, before U.S. financial markets open. The commercial stage specialty pharmaceutical company will follow the release with a management-hosted conference call and webcast to discuss financial and business results.
Interested parties can access the live webcast through the company's website at www.fennecpharma.com under the Investors & Media section's News & Events/Event Calendar page. Participants are advised to connect at least 15 minutes before the conference call to allow time for any necessary software downloads. A replay of the webcast will be available on the company's website for thirty days following the event.
Fennec Pharmaceuticals (NASDAQ: FENC) announced the commercial launch of PEDMARQSI in Germany through Norgine Pharmaceuticals. PEDMARQSI is the first and only approved therapy in the EU and UK for preventing hearing loss caused by cisplatin chemotherapy in pediatric cancer patients aged 1 month to <18 years with localized, non-metastatic solid tumors.
The launch follows a March 2024 exclusive licensing agreement with Norgine for Europe, Australia, and New Zealand. Fennec received $43 million upfront and could receive up to $230 million in additional milestone payments, plus double-digit tiered royalties starting in mid-teens and growing to mid-twenties.
Clinical trials demonstrated that PEDMARQSI reduced cisplatin-induced hearing loss by approximately 50% compared to cisplatin alone. The drug received European Commission marketing authorization in June 2023 under PUMA, with 10 years of data and market protection.
Fennec Pharmaceuticals (NASDAQ:FENC) announced that PEDMARQSI® has received a positive recommendation from NICE for use in England and Wales. The drug is the first and only treatment available within NHS for preventing cisplatin-induced hearing loss in children and young people aged 1 month to 17 years.
Two Phase 3 trials demonstrated approximately 50% reduction in cisplatin-induced ototoxicity compared to cisplatin alone. This addresses a significant unmet need as there were no previous preventative treatments available.
The announcement follows Fennec's March 2024 licensing agreement with Norgine Pharmaceuticals for commercialization in Europe, Australia, and New Zealand. The deal included a $43 million upfront payment and potential additional payments up to $230 million, plus double-digit tiered royalties starting in mid-teens.
FAQ
What is the current stock price of Fennec Pharmaceuticals (FENC)?
What is the market cap of Fennec Pharmaceuticals (FENC)?
